Preventing graft-versus-host disease in children after stem cell transplant
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial tests whether adding VIC-1911 to standard medications (cyclophosphamide and sirolimus) can help prevent graft-versus-host disease in children receiving a half-matched stem cell transplant from a family donor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 8 and 18 years old
- You have acute myeloid leukemia, high-risk acute lymphoblastic leukemia in remission, or certain types of myelodysplastic syndrome
- You have a family member who is a half-matched blood stem cell donor
- You are generally well enough to have a Karnofsky performance score of at least 80
- Your heart, lungs, kidneys, and liver are working well enough
- You cannot have serious heart disease or uncontrolled high blood pressure
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four medicines (cyclophosphamide, abatacept, vedolizumab, and ruxolitinib) to prevent graft-versus-host disease (GVHD) after a stem cell transplant for children and young adults with certain blood cancers. The goal is to see if this approach reduces the risk of GVHD, a serious complication where donor cells attack the body.
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
This trial tests if adding special immune cells (Treg cells) to a stem cell transplant from a half-matched donor can lower the risk of graft versus host disease (a serious side effect where donor cells attack the patient's body) in children and young adults with blood cancers.
This trial tests adding ruxolitinib to standard drugs (tacrolimus and methotrexate) to prevent graft-versus-host disease in children and young adults undergoing a stem cell transplant for acute leukemia or myelodysplastic syndrome. The goal is to lower the risk of GVHD and improve transplant outcomes.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
This trial tests a new way to prevent graft-versus-host disease (GVHD) after a stem cell transplant in people who have already received PD-1 immunotherapy. The goal is to make the transplant safer and more effective.
Hear when a new GVHD (Acute or Chronic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.